Apolipoprotein B-48 or its apolipoprotein B-100 equivalent mediates the binding of triglyceride-rich lipoproteins to their unique human monocyte-macrophage receptor

Arteriosclerosis, Thrombosis, and Vascular Biology
S H GianturcoW A Bradley

Abstract

Studies in animals and humans have demonstrated uptake of plasma chylomicrons (triglyceride-rich lipoprotein [TGRLP] of Sf>400) by accessible macrophages in vivo. One potential mechanism is via a unique receptor pathway we previously identified in human blood and THP-1 monocytes and macrophages for the lipoprotein lipase (LpL)- and apolipoprotein (apo) E-independent, high-affinity, specific binding of plasma chylomicrons and hypertriglyceridemic VLDL (HTG-VLDL) to cell-surface membrane-binding proteins (MBP 200, 235; apparent Mr 200, 235 kD on SDS-PAGE) that leads to lipid accumulation in vitro. Competitive binding studies reported here demonstrate that anti-apoB antibodies specifically block the high-affinity binding of TGRLP to this receptor on THP-1 cells and on ligand blots. LpL, which binds to an N-terminal domain of apoB, also inhibits TGRLP binding both to this site on THP-1s and to MBP 200, 235 by binding to apoB. Chylomicrons of Sf>1100 that contain apoB-48, but not apoB-100, bind specifically to MBP 200, 235, and this binding is blocked by anti-apoB IgG. In contrast, lactoferrin and heparin do not inhibit TGRLP binding. We conclude that the receptor-binding domain is within apoB-48 (or an equivalent in apoB-100) near ...Continue Reading

References

Jan 1, 1977·Annual Review of Biochemistry·J L Goldstein, M S Brown
Oct 1, 1992·Proceedings of the National Academy of Sciences of the United States of America·S TakahashiT Yamamoto
Oct 1, 1992·The Journal of Clinical Investigation·S C RumseyI J Goldberg
Jan 1, 1992·Annual Review of Nutrition·R BlomhoffK R Norum
Oct 1, 1991·Proceedings of the National Academy of Sciences of the United States of America·U BeisiegelG Bengtsson-Olivecrona
Aug 1, 1989·Proceedings of the National Academy of Sciences of the United States of America·R C KowalM S Brown
Nov 1, 1988·The Journal of Clinical Investigation·S H GianturcoW A Bradley
Sep 1, 1988·Arteriosclerosis : an Official Journal of the American Heart Association, Inc·S EisenbergT Vogel
Dec 1, 1987·The Journal of Clinical Investigation·M S WeintraubJ L Breslow
Jan 1, 1986·Methods in Enzymology·S H Gianturco, W A Bradley
Nov 1, 1985·Arteriosclerosis : an Official Journal of the American Heart Association, Inc·R J Havel
Feb 1, 1985·The Journal of Clinical Investigation·E S KrulG Schonfeld
May 16, 1995·Biochemical and Biophysical Research Communications·M P RamprasadW A Bradley

❮ Previous
Next ❯

Citations

Jun 22, 1999·Clinical Cardiology·S H Gianturco, W A Bradley
Mar 10, 2001·Diabetes/metabolism Research and Reviews·G H Tomkin, D Owens
Jul 5, 2001·Biochemical and Biophysical Research Communications·A M SawkaT O'Brien
Aug 14, 2002·Irish Journal of Medical Science·G H Tomkin
Mar 2, 2005·Irish Journal of Medical Science·G H Tomkin
Oct 5, 2011·Current Cardiology Reports·Beatriz G Talayero, Frank M Sacks
Dec 3, 1999·Journal of Internal Medicine·F Karpe
Nov 22, 2000·Current Opinion in Lipidology·R J Havel
Jul 21, 2011·Journal of Lipids·You-Guo Niu, Rhys D Evans
Nov 2, 2006·PLoS Biology·Zahedi MujawarDmitri Sviridov
Mar 8, 2013·Future Cardiology·Yu KataokaStephen J Nicholls
Jun 15, 2000·Proceedings of the National Academy of Sciences of the United States of America·M L BrownS H Gianturco
Mar 19, 2004·QJM : Monthly Journal of the Association of Physicians·C PhillipsG H Tomkin
Aug 19, 2007·Clinical Therapeutics·Terry A JacobsonErnst J Schaefer
Dec 4, 2016·Bioorganic & Medicinal Chemistry Letters·Werner J GeldenhuysPrabodh Sadana
Apr 18, 2003·Journal of Lipid Research·Go HaraguchiWilliam A Bradley
Apr 11, 2003·Diabetologia·E Shafrir, I Raz
Apr 20, 2001·Biochemistry and Cell Biology = Biochimie Et Biologie Cellulaire·K SuzukiF Ohsuzu
Nov 29, 2015·Clinical Chemistry·Sarah K Anisowicz, Jude M Abadie
Mar 4, 2011·The American Journal of Clinical Nutrition·Lourdes M VarelaFrancisco J G Muriana
Jun 9, 2005·Journal of Atherosclerosis and Thrombosis·Akio Kawakami, Masayuki Yoshida
Sep 18, 2002·Journal of Lipid Research·Kaspar K Berneis, Ronald M Krauss
Jun 6, 2000·The Journal of Infectious Diseases·W KhovidhunkitC Grunfeld
Jan 25, 2002·Annals of the New York Academy of Sciences·A TanakaF Numano
Sep 11, 2004·Biochemical and Biophysical Research Communications·Bin ZhaoHoward S Kruth
Nov 19, 2010·Forensic Science International : Synergy·Katsuyuki NakajimaMasaki Q Fujita
Feb 15, 2008·Diabetes Care·Gerald H Tomkin

❮ Previous
Next ❯

Related Concepts

Related Feeds

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.

Atherosclerosis Disease Progression

Atherosclerosis is the buildup of plaque on artery walls, causing stenosis which can eventually lead to clinically apparent cardiovascular disease. Find the latest research on atherosclerosis disease progression here.